Oramed Pharmaceuticals Inc.

ORMPNASDAQHealthcare● Active

$3.64

$-0.07(-1.89%)

Market Cap$148970935

P/E Ratio—

52W High$5.01

52W Low$1.98

Avg Volume155K

Open$3.68

Beta1.24

Free Cash Flow Financials Revenue

Oramed Pharmaceuticals Inc. (ORMP) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ORMP · free cash flow · updated Jun 9, 2026

Core FCF metrics

ORMP · FCF · TTM · margin & CAGR

Free cash flow was −$11.1M for FY2025 (fiscal year ending 2025-12-31), down 31.4% year-over-year The FCF margin was -553.9%.

FY2025 Free Cash Flow−$11.1M▼ -31.4% YoY

Trailing 12M (TTM)−$8.7Mtrailing 4 quarters sum

FCF Margin-553.9%−$11.1M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ORMP · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$9.1M(2M)−$11.1M▼ 31.4%-553.9%

FY2024−$8.4M(0M)−$8.4M▲ +20.1%—

FY2023−$10.3M(0M)−$10.5M▲ +63.9%-787.2%

FY2022−$28.7M(0M)−$29.2M▼ 35.4%—

FY2021−$21.2M(0M)−$21.6M▼ 72.1%-797.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ORMP · P/FCF · FCF yield · FCF per share

Oramed Pharmaceuticals Inc. (ORMP) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ORMP · cash flow statement · operating / investing / financing

For FY2025, Oramed Pharmaceuticals Inc. generated −$9.1M in operating cash flow and spent 2M in capital expenditures, yielding −$11.1M in free cash flow.

Operating Activities

−$9.1M

Cash from core business operations

2025-12-31

Investing Activities

+$5.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$4.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$9.1M) − |CapEx| (2M) = FCF (−$11.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ORMP vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Oramed Pharmaceuticals Inc.YOU

ORMP

−$11.1M-31.4%-553.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Oramed Pharmaceuticals Inc. (ORMP) reported free cash flow of −$11.1M for FY2025 (fiscal year ending 2025-12-31), down 31.4% year-over-year. The FCF margin was -553.9%.

Based on available data, Oramed Pharmaceuticals Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $4.6M in FY2016.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ORMP free cash flow · 8 questions

Oramed Pharmaceuticals Inc. free cash flow was −$11.1M for FY2025, down 31.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$8.7M.

ORMP free cash flowORMP FCFORMP FCF 2025ORMP free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Oramed Pharmaceuticals Inc. · Oramed Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026